In the BOLERO-2 trial, everolimus (EVE) plus exemestane (EXE) more than doubled median progression free survival (PFS) vs EXE and was generally well-tolerated in elderly patients (pts) with HR+, HER2− advanced breast cancer (ABC) progressing on prior NSAIs. However, there is limited real world data on the safety profile of EVE+ EXE in elderly pts. This subgroup analysis in BALLET trial assessed the safety of EVE+ EXE in pts⩾ 70Y of age with ABC progressing on prior NSAIs.

Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC)

Clara Natoli;
2015

Abstract

In the BOLERO-2 trial, everolimus (EVE) plus exemestane (EXE) more than doubled median progression free survival (PFS) vs EXE and was generally well-tolerated in elderly patients (pts) with HR+, HER2− advanced breast cancer (ABC) progressing on prior NSAIs. However, there is limited real world data on the safety profile of EVE+ EXE in elderly pts. This subgroup analysis in BALLET trial assessed the safety of EVE+ EXE in pts⩾ 70Y of age with ABC progressing on prior NSAIs.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11564/699348
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact